A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

Breast Cancer Clinical Trial

— FAPrimo  

Official title:

A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients With Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05784597
• Other study ID #: PH-FAPGA-01/22
• Status: Recruiting
• Phase: Phase 1
• Start date: April 27, 2023
• Est. completion date: October 2024

Study information

• Verified date: April 2024
• Source: Philogen S.p.A.
• Contact: Jacqueline Mock, PhD
• Phone: +41 43 544 88 02
• Email: regulatory[@]philogen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.

Description:

Phase I, multicenter study in patients with a confirmed diagnosis of solid tumor among breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma, requiring clinical staging for nodal staging and/or metastatic disease (based on institutional practice and risk stratification). All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq). [68Ga]Ga-OncoFAP biodistribution, PK, and dosimetry of [68Ga]Ga-OncoFAP will be assessed based on a series of PET/CT scans, blood and urine sampling.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with a confirmed diagnosis of breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma. Confirmation by histopathology is required for breast, colorectal and oesophageal cancer. For pancreatic adenocarcinoma, confirmation by histopathology or cytology obtained by endoscopic ultrasound is accepted.

2. Requirement for diagnostic imaging or imaging performed within 4 weeks prior to the [68Ga]Ga-OncoFAP-PET/CT scan for staging.

3. Male or non-pregnant and non-breastfeeding female.

4. For female patients: negative serum pregnancy test for women of childbearing potential* (WOCBP). WOCBP must agree to use, from the screening to six months following the study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

5. For male patients: male subject able to father children must agree to practice effective contraception for three months starting from the study drug administration.

6. Age 18 - 75

7. ECOG = 1

8. Patient must not have any concomitant infections or active concomitant disease.

9. Life expectancy of more than 12 weeks.

10. Ability to undergo imaging study procedures.

11. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.

12. Willingness and ability to comply with the scheduled visits, plan, laboratory tests and other study procedures.

• Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).

Exclusion Criteria:

1. Chronically impaired renal function as expressed by creatinine clearance < 60 mL/min or serum creatinine > 1.5 x ULN.

2. Presence of active hepatitis.

3. Presence of significant cardiac disorders (congestive heart failure, NYHA class III-IV, myocardial infarction within one year prior to study entry, uncontrolled hypertension, or arrhythmia).

4. Pregnant or breastfeeding during participation in the study.

5. Any concomitant condition which in the opinion of investigators makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.

6. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of the study drug. Minimally invasive procedures such as biopsies are not considered as exclusion criteria.

7. Serious, non-healing wound, ulcer, or bone fracture.

8. Allergy to study medication or excipients in study medication.

9. Any anti-cancer therapy (e.g. cytotoxic chemotherapy, immunotherapy, radiation, surgery, etc.) within 3 weeks before [68Ga]Ga-OncoFAP-PET/CT scan

10. Subject has received, or is scheduled to receive, another investigational medicinal product (IMP) from 1 month before [68Ga]Ga-OncoFAP injection to end of study participation.

Related Conditions & MeSH terms

• Breast Cancer
• Colorectal Cancer
• Oesophageal Cancer
• Pancreas Adenocarcinoma

Intervention

Drug:
• [68Ga]Ga-OncoFAP administration
All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)

Locations

Country	Name	City	State
Italy	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"	Meldola
Italy	IRCCS San Raffaele	Milano
Italy	Istituto Nazionale dei Tumori | Fondazione IRCCS	Milano
Italy	Azienda Ospedaliero Universitaria Pisana	Pisa
Italy	Istituto Clinico Humanitas	Rozzano	Milano

Sponsors (1)

Lead Sponsor	Collaborator
Philogen S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety (AE)	Safety of administration of 68Ga-OncoFAP, assessed based on Common Toxicity Criteria (CTCAE version 5.0)	Throughout study, until a maximum of 8 days after the completion of each patient
Primary	Cohort A: Dosimetry - Effective dose equivalent (mSv)	Effective dose equivalent (mSv) of normal organs following administration of a single dose of [68Ga]Ga-OncoFAP, for patients in cohort A	Assessed on day 1
Primary	Cohort A: Dosimetry - Absorbed doses (mGy)	Absorbed doses (mGy) of normal organs following administration of a single dose of [68Ga]Ga-OncoFAP, for patients in cohort A	Assessed on day 1
Secondary	Biodistribution profile: SUVmax	Uptake of [68Ga]Ga-OncoFAP in terms of SUVmax	Assessed on day 1
Secondary	Biodistribution profile: SUVmean	Uptake of [68Ga]Ga-OncoFAP in terms of SUVmean	Assessed on day 1
Secondary	Biodistribution profile: SUVsd	Uptake of [68Ga]Ga-OncoFAP in terms of SUVsd	Assessed on day 1
Secondary	PK	Pharmacokinetics of [68Ga]Ga-OncoFAP based on measurement of residual radioactivity in the blood over time [MBq/mL	Assessed on day 1
Secondary	Excretion	Metabolism and excretion of [68Ga]Ga-OncoFAP based on radioactivity measurements on urine collected at defined timepoints	Assessed on day 1
Secondary	Immunopathology staining	Correlation of [68Ga]Ga-OncoFAP uptake with immunopathology staining if and when surgical or biopsy specimen are available	Assessed on day 1
Secondary	Lesion detection rate	Lesion detection rate compared to standard imaging	Assessed on day 1